2023 World Conference on Lung Cancer (Posters)-EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC

EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy and safety of adding amivantamab as a salvage therapy for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who had disease progression after treatment with EGFR TKIs (osimertinib or mobocertinib). The study included 13 patients, with 8 in Group A (osimertinib) and 5 in Group B (mobocertinib), who received amivantamab on top of their previous EGFR TKI. The objective response rate (ORR) was 37.5% in Group A and 60% in Group B. The median duration of therapy was 2.3 months in Group A and 5.5 months in Group B. The median progression-free survival was 4.7 months in both groups. The safety profile of amivantamab was mainly driven by grade 3 toxicity, such as nausea, diarrhea, and skin rash. A total of 16% of patients experienced a grade 3 infusion reaction. Overall, adding amivantamab to previous EGFR TKI treatment was found to be feasible and showed clinically significant response rates. The study suggests further research to profile the subgroup of patients and conduct valid prospective analysis.

Asset Subtitle

Nir Peled

Meta Tag

Speaker Nir Peled

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

amivantamab

salvage therapy

EGFR-mutated non-small cell lung cancer

disease progression

EGFR TKIs

osimertinib

mobocertinib

objective response rate

progression-free survival

grade 3 toxicity